Back to Search
NIZAR JACQUES BAHLIS, MD
MD
Hematology & Oncology Physician
NPI: 1538669296Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
78362(GA)
Research & Publications (20)
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.
PMID 18721762·Biol Blood Marrow Transplant·2008
4-observational
Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?
PMID 16715110·Bone Marrow Transplant·2006
6-review
N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells.
PMID 16019536·Leuk Lymphoma·2005
8-other
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
PMID 19656151·Br J Haematol·2009
3-trial
pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.
PMID 19562614·Leuk Lymphoma·2009
8-other
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
PMID 19545290·Br J Haematol·2009
8-other
Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).
PMID 19423744·Blood·2009
3-trial
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.
PMID 19332768·Blood·2009
3-trial
The relationships among physiologic variables, quality of life, and fatigue in patients with multiple myeloma.
PMID 19273410·Oncol Nurs Forum·2009
8-other
Preventing and treating chronic disorders using the modified vaccination technique.
PMID 19273320·Front Biosci (Landmark Ed)·2009
6-review
Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.
PMID 18640572·Biol Blood Marrow Transplant·2008
3-trial
New vaccination technology for endogenous antigen-derived ailments.
PMID 18240096·IDrugs·2008
6-review
High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
PMID 18215782·Biol Blood Marrow Transplant·2008
3-trial
Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.
PMID 17580259·Biol Blood Marrow Transplant·2007
8-other
O6-benzylguanine and BCNU in multiple myeloma: a phase II trial.
PMID 17354015·Cancer Chemother Pharmacol·2007
3-trial
CD28-mediated regulation of multiple myeloma cell proliferation and survival.
PMID 17311991·Blood·2007
8-other
Overnight storage of autologous stem cell apheresis products before cryopreservation does not adversely impact early or long-term engraftment following transplantation.
PMID 16980991·Bone Marrow Transplant·2006
8-other
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
PMID 16467197·Blood·2006
3-trial
Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.
PMID 16062177·Bone Marrow Transplant·2005
8-other
Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals.
PMID 15693136·Cancer Immunol Immunother·2005
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- WINSHIP CANCER INSTITUTE 1365 CLIFTON RD BUILDING C
ATLANTA, GA 30322 - Phone
- (403) 608-8861
Quick Facts
- NPI
- 1538669296
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile